The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNatwest Regulatory News (NWG)

Share Price Information for Natwest (NWG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 289.80
Bid: 274.00
Ask: 291.00
Change: 0.00 (0.00%)
Spread: 17.00 (6.204%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 289.80
NWG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

ESTIMATED IMPACT OF TENDER OFFERS

23 Sep 2020 18:12

RNS Number : 9328Z
NatWest Group plc
23 September 2020
 

NatWest Group plc

23 September 2020

NATWEST GROUP PLC - ESTIMATED IMPACT OF TENDER OFFERS FOR CERTAIN OF ITS OUTSTANDING NOTES

Further to the announcement dated 22 September 2020 "Results of tender offers for certain of its outstanding notes", NatWest Group plc confirms that it has accepted $1,977,326,000 in aggregate principal amount of the securities that were validly tendered. This includes an amount due under Guaranteed Delivery of $9,418,000, which is due to be confirmed at 10pm, London time, 23 September 2020. The principal amount outstanding prior to the tender offer was $4,405,319,000.

NatWest Group plc undertook the offers in order to provide the holders of the outstanding notes with an opportunity to have their notes repurchased while maintaining a prudent approach to the management of NatWest Group plc's capital position.

NatWest Group plc estimates the impact of this transaction will be a charge to income in its Q3 results of approximately £325 million with the final charge dependent on foreign exchange rate movements until the settlement date of 24 September 2020. After taking into account the estimated effects of taxation, and based on risk weighted assets of £181.5 billion as reported for 30 June 2020, this would equate to a reduction in the CET1 capital ratio of approximately 15 bps.

 

FURTHER INFORMATION

Investor Relations

Alexander Holcroft

Head of Investor Relations

+44 (0) 20 7672 1758

Paul Pybus

Head of Debt Investor Relations

+44 (0)776 916 1183

 

Legal Entity Identifiers

NatWest Group plc 2138005O9XJIJN4JPN90

 

Forward-looking statements

This document contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, such as statements that include, without limitation, the words 'expect', 'estimate', 'project', 'anticipate', 'commit', 'believe', 'should', 'intend', 'plan', 'could', 'probability', 'risk', 'Value-at-Risk (VaR)', 'target', 'goal', 'objective', 'may', 'endeavour', 'outlook', 'optimistic', 'prospects' and similar expressions or variations on these expressions. These statements concern or may affect future matters, such as NatWest Group's future economic results, business plans and strategies. In particular, this document may include forward-looking statements relating to NatWest Group in respect of, but not limited to: its regulatory capital position and related requirements, its financial position, profitability and financial performance (including financial, capital and operational targets), its access to adequate sources of liquidity and funding, increasing competition from new incumbents and disruptive technologies, its exposure to third party risks, its ongoing compliance with the UK ring-fencing regime and ensuring operational continuity in resolution, its impairment losses and credit exposures under certain specified scenarios, substantial regulation and oversight, ongoing legal, regulatory and governmental actions and investigations, the transition of LIBOR and IBOR rates to alternative risk free rates and NatWest Group's exposure to economic and political risks (including with respect to terms surrounding Brexit and climate change), operational risk, conduct risk, cyber and IT risk, key person risk and credit rating risk. Forward-looking statements are subject to a number of risks and uncertainties that might cause actual results and performance to differ materially from any expected future results or performance expressed or implied by the forward-looking statements. Factors that could cause or contribute to differences in current expectations include, but are not limited to, the final number of PPI claims and their amounts, the level and extent of future impairments and write-downs, including with respect to goodwill, legislative, political, fiscal and regulatory developments, accounting standards, competitive conditions, technological developments, interest and exchange rate fluctuations, general economic and political conditions and the uncertainty surrounding the Covid-19 pandemic and its impact on NatWest Group. These and other factors, risks and uncertainties that may impact any forward-looking statement or NatWest Group plc's actual results are discussed in NatWest Group plc's UK 2019 Annual Report and Accounts (ARA), NatWest Group plc's Interim Results for Q1 2020 and NatWest Group plc's Interim Results for H1 2020 and materials filed with, or furnished to, the US Securities and Exchange Commission, including, but not limited to, NatWest Group plc's most recent Annual Report on Form 20-F and Reports on Form 6-K. The forward-looking statements contained in this document speak only as of the date of this document and NatWest Group plc does not assume or undertake any obligation or responsibility to update any of the forward-looking statements contained in this document, whether as a result of new information, future events or otherwise, except to the extent legally required.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TENUORBRRKUKUAR
Date   Source Headline
26th Apr 20247:00 amRNSNWG plc Q1 2024 Interim Management Statement
25th Apr 20245:15 pmRNSTransaction in Own Shares
24th Apr 20245:16 pmRNSTransaction in Own Shares
23rd Apr 20245:22 pmRNSTransaction in Own Shares
23rd Apr 20242:22 pmRNSResult of AGM
23rd Apr 20242:02 pmRNSDividend Declaration
23rd Apr 202411:01 amRNSAGM Statement
19th Apr 20245:27 pmRNSTransaction in Own Shares
18th Apr 20245:54 pmRNSTransaction in Own Shares
17th Apr 20245:40 pmRNSTransaction in Own Shares
15th Apr 20245:15 pmRNSTransaction in Own Shares
12th Apr 20245:12 pmRNSTransaction in Own Shares
11th Apr 20245:10 pmRNSTransaction in Own Shares
11th Apr 202411:43 amRNSBlock Listing Six Monthly Return
10th Apr 20245:15 pmRNSTransaction in Own Shares
9th Apr 20245:20 pmRNSTransaction in Own Shares
8th Apr 20245:35 pmRNSTransaction in Own Shares
5th Apr 202410:32 amRNSHolding(s) in Company - HMT shareholding
4th Apr 20245:39 pmRNSTransaction in Own Shares
4th Apr 20248:00 amRNSDirector Declaration
3rd Apr 20245:13 pmRNSTransaction in Own Shares
3rd Apr 20242:00 pmRNSDirector/PDMR Shareholding
2nd Apr 20246:04 pmRNSTransaction in Own Shares
28th Mar 20245:17 pmRNSTransaction in Own Shares
28th Mar 20241:55 pmRNSTotal Voting Rights
27th Mar 20245:31 pmRNSTransaction in Own Shares
27th Mar 20244:21 pmRNSHolding(s) in Company
25th Mar 20242:00 pmRNSDirector/PDMR Shareholding
25th Mar 202410:30 amRNSHolding(s) in Company - HMT shareholding
22nd Mar 20245:47 pmRNSTransaction in Own Shares
22nd Mar 20249:30 amRNSDirector Declaration
21st Mar 20245:49 pmRNSTransaction in Own Shares
20th Mar 20245:46 pmRNSTransaction in Own Shares
19th Mar 20245:47 pmRNSTransaction in Own Shares
19th Mar 20249:01 amRNSHoldings in Company
18th Mar 20245:45 pmRNSTransaction in Own Shares
18th Mar 20244:00 pmRNSNotice of AGM
18th Mar 202412:00 pmRNSDirector/PDMR Shareholding
15th Mar 20245:32 pmRNSTransaction in Own Shares
15th Mar 202410:19 amRNSHolding(s) in Company - HMT shareholding
14th Mar 20245:48 pmRNSTransaction in Own Shares
13th Mar 20245:13 pmRNSTransaction in Own Shares
12th Mar 20245:08 pmRNSTransaction in Own Shares
11th Mar 20245:39 pmRNSTransaction in Own Shares
8th Mar 20245:14 pmRNSTransaction in Own Shares
8th Mar 20242:15 pmRNSDirector/PDMR Shareholding
8th Mar 202412:41 pmRNSHolding(s) in Company
7th Mar 20245:26 pmRNSTransaction in Own Shares
7th Mar 202412:13 pmRNSNotice of Redemption
6th Mar 20245:23 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.